Cargando…

The target therapy of ovarian clear cell carcinoma

Clear cell adenocarcinoma (CCC) of the ovary accounts for 10% of epithelial ovarian cancer and is a distinct entity from other epithelial ovarian carcinomas. It arises from the endometriosis. CCC has specific biological and clinical behavior. Compared with other histological types, CCC shows a chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ying, Li, Yan, Pan, Lingya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181630/
https://www.ncbi.nlm.nih.gov/pubmed/25285014
http://dx.doi.org/10.2147/OTT.S49993
_version_ 1782337395250692096
author Jin, Ying
Li, Yan
Pan, Lingya
author_facet Jin, Ying
Li, Yan
Pan, Lingya
author_sort Jin, Ying
collection PubMed
description Clear cell adenocarcinoma (CCC) of the ovary accounts for 10% of epithelial ovarian cancer and is a distinct entity from other epithelial ovarian carcinomas. It arises from the endometriosis. CCC has specific biological and clinical behavior. Compared with other histological types, CCC shows a chemoresistant phenotype, which leads to poorer prognosis. Thus, development of new target-based therapies remains an unmet need for these patients. Mutations in the gene ARID1A have been found to occur in high frequency in CCC. The majority of these mutations lead to a loss of expression of the ARID1A protein, which is a subunit of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex and considered as a bona fide tumor suppressor. Upregulation of the PIK3/AKT/mTOR pathway, particularly through mutations of PIK3CA and inactivation of PTEN, is involved in tumorigenesis of CCC. Targeting angiogenesis, the Met protooncogene pathway, and HER2 are also discussed in this review.
format Online
Article
Text
id pubmed-4181630
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41816302014-10-03 The target therapy of ovarian clear cell carcinoma Jin, Ying Li, Yan Pan, Lingya Onco Targets Ther Review Clear cell adenocarcinoma (CCC) of the ovary accounts for 10% of epithelial ovarian cancer and is a distinct entity from other epithelial ovarian carcinomas. It arises from the endometriosis. CCC has specific biological and clinical behavior. Compared with other histological types, CCC shows a chemoresistant phenotype, which leads to poorer prognosis. Thus, development of new target-based therapies remains an unmet need for these patients. Mutations in the gene ARID1A have been found to occur in high frequency in CCC. The majority of these mutations lead to a loss of expression of the ARID1A protein, which is a subunit of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex and considered as a bona fide tumor suppressor. Upregulation of the PIK3/AKT/mTOR pathway, particularly through mutations of PIK3CA and inactivation of PTEN, is involved in tumorigenesis of CCC. Targeting angiogenesis, the Met protooncogene pathway, and HER2 are also discussed in this review. Dove Medical Press 2014-09-23 /pmc/articles/PMC4181630/ /pubmed/25285014 http://dx.doi.org/10.2147/OTT.S49993 Text en © 2014 Jin et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Jin, Ying
Li, Yan
Pan, Lingya
The target therapy of ovarian clear cell carcinoma
title The target therapy of ovarian clear cell carcinoma
title_full The target therapy of ovarian clear cell carcinoma
title_fullStr The target therapy of ovarian clear cell carcinoma
title_full_unstemmed The target therapy of ovarian clear cell carcinoma
title_short The target therapy of ovarian clear cell carcinoma
title_sort target therapy of ovarian clear cell carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181630/
https://www.ncbi.nlm.nih.gov/pubmed/25285014
http://dx.doi.org/10.2147/OTT.S49993
work_keys_str_mv AT jinying thetargettherapyofovarianclearcellcarcinoma
AT liyan thetargettherapyofovarianclearcellcarcinoma
AT panlingya thetargettherapyofovarianclearcellcarcinoma
AT jinying targettherapyofovarianclearcellcarcinoma
AT liyan targettherapyofovarianclearcellcarcinoma
AT panlingya targettherapyofovarianclearcellcarcinoma